Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents

British Journal of Pharmacology

Volumn 138, Issue 5, 2003, Pages 819-830

  Becker, Erika M ^a   Lovejoy, David B ^b,c   Greer, Judith M ^a   Watts, Ralph ^b,c   Richardson, Des R ^b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b HEART RESEARCH INSTITUTE   (Australia)

^c CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

Anti tumour agents; Chemotherapy; Fe metabolism; Iron (Fe) chelators

Indexed keywords

2 PYRIDYLCARBOXALDEHYDE; 2 PYRIDYLCARBOXALDEHYDE ISONICOTINOYL HYDRAZONE; 2 QUINOLINECARBOXALDEHYDE; 2 QUINOLINECARBOXALDEHYDE ISONICOTINOYL HYDRAZONE; ALDEHYDE DERIVATIVE; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CHELATING AGENT; DI 2 PYRIDYLKETONE; DIPYRIDYLKETONE ISONICOTINOYL HYDRAZONE DERIVATIVE; HYDRAZIDE DERIVATIVE; IRON; IRON CHELATE; ISONIAZID DERIVATIVE; LEUCINE; LIGAND; MESSENGER RNA; REGULATOR PROTEIN; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG; URIDINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CELL CYCLE; CELL PROLIFERATION; CHEMICAL REACTION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IRON CHELATION; IRON TRANSPORT; LIPOPHILICITY; MEMBRANE PERMEABILITY; MITOSIS INHIBITION; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING;

ANTINEOPLASTIC AGENTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDRAZONES; IRON CHELATING AGENTS; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0037351292     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705089     Document Type: Article

References (67)

1. ABBOUD, S. & HAILE, D.J. (2000). A novel mammalian iron regulated protein involved in intracellular iron metabolism. J. Biol. Chem., 275, 19906-19912.
2. ANTHOLINE, W., KNIGHT, J., WHELAN, H. & PETERING, D.H. (1977). Studies of the reaction of 2-formylpyridine thiosemicarbazone and its iron and copper complexes with biological systems. Mol. Pharmacol., 13, 89-98.
3. BACCHI, A., CARCELLI, M., COSTA, M., PELAGATTI, P., PELIZZI, C. & PELIZZI, G. (1996). Versatile ligand behaviour of phenyl 2-pyridyl ketone benzoyl hydrazone in palladium(II) complexes. J. Chem. Soc. Dalton Trans., 22, 4239-4244.
4. BAKER, E., PAGE, M., TORRANCE, J. & GRADY, R. (1985). Effect of desferrioxamine, rhodotorulic acid and cholylhydroxamic acid on transferrin and iron exchange with hepatocytes in culture. Clin. Physiol. Biochem., 3, 277-288.
5. BAKER, E., RICHARDSON, D.R., GROSS, S. & PONKA, P. (1992). Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology, 15, 492-501.
6. BECKER, E. & RICHARDSON, D.R. (1999). Development of novel aroylhydrazone ligands for iron chelation therapy: The 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J. Lab. Clin. Med., 134, 510-521.
7. BECTON, D.L. & BRYLES, P. (1988). Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res., 48, 7189-7192.
8. BERNHARDT, P.V., CHIN, P. & RICHARDSON, D.R. (2001). Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): Serendipitous identification of diacylhydrazone ligands with high iron chelation efficacy. J. Biol. Inorg. Chem., 6, 801-809.
9. BLATT, J. (1994). Deferoxamine in children with recurrent neuroblastoma. Anticancer Res., 14, 2109-2112.
10. BLATT, J. & STITELY, S. (1987). Antineuroblastoma activity of desferrioxamine in human cell lines. Cancer Res., 47, 1749-1750.
11. BOTTOMLEY, S.S., WOLFE, L.C. & BRIDGES, K.R. (1985). Iron metabolism in K562 erythroleukemia cells. J. Biol. Chem., 260, 6811-6815.
12. BRITTENHAM, G.M. (1990). Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. Semin. Hematol., 27, 112-116.
13. BROTO, P., MOREAU, G. & VANDYCKE, C. (1984). Molecular structures: Perception, autocorrelation descriptor and sar studies. System of atomic contributions for the calculation of the n-octanol/water partition coefficients. Eur. J. Med. Chem. Chim. Theor., 19, 71-78.
14. BURGER, R.M., ALDER, A.D., HORWITZ, S.B., MIMS, W.B. & PEISACH, J. (1981). Demonstration of nitrogen coordination in metal-bleomycin complexes by electron spin-echo envelope spectroscopy. Biochemistry, 20, 1701-1704.
15. CORY, J.G., CORY, A.H., RAPPA, G., LORICO, A., LIU, M.C., LIN, T.S. & SARTORELLI, A.C. (1994). Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem. Pharmacol., 48, 335-344.
16. DARNELL, G. & RICHARDSON, D.R. (1999). The potential of the iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood, 94, 781-792.
17. DECONTI, R.C., TOFTNESS, B.R., AGRAWAL, K.C., TOMCHICK, R., MEAD, J.A.R., BERTINO, J.R., SARTORELLI, A.C. & CREASEY, W.A. (1972). Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res., 32, 1455-1462.
18. DEZZA, L., CAZZOLA, M., DANOVA, M., CARLO-STELLA, C., BERGAMASCHI, G., BRUGNATELLI, S., INVERNIZZI, R., MAZZINI, G., RICCARDI, A. & ASCARI, E. (1989). Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies. Leukemia, 3, 104-107.
19. DONFRANCESCO, A., DEB, G., DOMINICI, C., ANGIONI, A., CANIGLIA, M., DE SIO, L., FIDANI, P., AMICI, A. & HELSON, L. (1992). Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECat): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am. J. Clin. Oncol., 15, 319-322.
20. DONFRANCESCO, A., DEB, G., DOMINICI, C., PILEGGI, D., CASTELLO, M.A. & HELSON, L. (1990). Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res., 50, 4929-4930.
21. DONFRANCESCO, A., DE BERNARDI, B., CARLI M., MANCINI, A., NIGRO, M., DE SIO, L., CASALE, F., BAGNULO, S., HELSON, L. & DEB, G. (1995). Deferoxamine (D) followed by cytoxan (C), etoposide (E), carboplatin (Ca), thio-TEPA (T), induction regimen in advanced neuroblastoma. Eur. J. Cancer, 31A, 612-615.
22. EL-DEIRY, W.S., TOKINO, T., VELCULESCU, V.E., LEVY, D.B., PARSONS, R., TRENT, J.M., LIN, D., MERCER, W.E., KINZLER, K.W. & VOGELSTEIN, B. (1993). WAF1, a potent mediator of p53 tumor suppression. Cell, 75, 817-825.
23. ESTROV, Z., TAWA, A., WANG, X-H., DUBE, I.D., SULH, H., COHEN, A., GELFAND, E.W. & FREEDMAN, M.H. (1987). In vivo and in vitro effects of desferrioxamine in neonatal acute leukemia. Blood, 69, 757-761.
24. FINCH, R.A., LIU, M-C., CORY, A.H., CORY, J.G. & SARTORELLI, A.C. (1999). Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): An inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzyme Regul., 39, 3-12.
25. FINCH, R.A., LIU, M-C., GRILL, S.P., ROSE, W.C., LOOMIS, R., VASQUEZ, K.M., CHENG, Y-C. & SARTORELLI, A.C. (2000). Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol., 59, 983-991.
26. GAO, J. & RICHARDSON, D.R. (2001). The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents IV. The mechanisms involved in inhibiting cell cycle progression. Blood, 98, 842-850.
27. GHOSE, A.K. & CRIPPEN, G.M. (1987). Atomic physiochemical parameters for 3-dimensional-structure directed quantitative structure-activity-relationships 2. Modelling dispersive and hydrophobic interactions. J. Chem. Inf. Comput. Sci., 27, 21-35.
28. GREEN, D.A., ANTHOLINE, W.E., WONG, S.J., RICHARDSON, D.R. & CHITAMBAR, C.R. (2001). Ribonucleotide reductase as a preferential target for the inhibition of leukemic cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class. Clin. Cancer Res., 7, 3574-3579.
29. HENRY, C., RAKBA, N., IMBERT, D., THOMAS, F., BARET, P., SERRATRICE, G., GAUDE, D., PIERRE, J.L., WARD, R.J., CRICHTON, R.R. & LESCOAT, G. (2001). New 8-hydroxyquinoline and catecholate iron chelators: influence of their partition coefficient on their biological activity. Biochem. Pharmacol., 62, 1355-1362.
30. HENTZE, M.W. & KÜHN, L.C. (1996). Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. U.S.A., 93, 8175-8182.
31. HERSHKO, C. (1994). Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillière's Clin. Haematol., 7, 965-1000.
32. HERSHKO, C, AVRAMOVICI-GRISARU, S., LINK, G., GELFAND, L. & SAREL, S. (1981). Mechanisms of in vivo chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J. Lab. Clin. Med., 98, 99-108.
33. HIRLING, H., HENDERSON, B.R. & KÜHN, L.C. (1994). Mutational analysis of the [4Fe-4S] cluster converting iron regulatory factor from its RNA-binding form to cytoplasmic aconitase. EMBO J., 13, 453-461.
34. IACOPETTA, B.J. & MORGAN, E.H. (1983). The kinetics of transferrin endocytosis and iron uptake from transferrin in rabbit reticulocytes. J. Biol. Chem., 258, 9108-9115.
35. JOHNSON, D.K., MURPHY, T.B., ROSE, N.I., GOODWIN, W.H. & PICKART, L. (1982). Cytotoxic chelators and chelates. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper (II) complex of salicylaldehyde benzoyl hydrazone. Inorg. Chim. Acta, 67, 159-162.
36. KARIN, M. & MINTZ, B. (1981). Receptor-mediated endocytosis of transferrin in totipotent mouse teratocarcinoma cells. J. Biol. Chem., 256, 3245-3252.
37. KASTAN, M.B., ZHAN, Q., EI-DEIRY, W.S., CARRIER, F., JACKS, T., WALSH, W.V., PLUNKETT, B.S., VOGELSTEIN, B. & FORNACE, JR, A.J. (1992). A mammalian cell cycle check point pathway utilizing p53 and gadd45 is defective in ataxia telangiectasia. Cell, 71, 587-597.
38. KEMP, J.D., CARDILLO, T., STEWART, B.C., KEHRBERG, E., WEINER, G., HEDLUND, B. & NAUMANN, P.W. (1995). Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Res., 55, 3817-3824.
39. KEMP, J.D., THORSON, J.A., STEWART, B.C. & NAUMANN, P.W. (1992). Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: evidence for a threshold model of iron deprivation toxicity. Cancer Res., 52, 4144-4148.
40. KICIC, A., CHUA, A.C.G. & BAKER, E. (2001). Effect of iron chelators on proliferation and iron uptake in hepatoma cells. Cancer, 92, 3093-3110.
41. KRAKOFF, I.H., ETCUBANAS, E., TAN, C., MAYER, K., BETHUNE, V. & BURCHENAI, J.H. (1974). Clinical trial of 5-hydroxypicolinaldehyde thiosemicarbazone (5-HP: NSC-107392), with special reference to its Fe chelating properties. Cancer Chemother. Rep., 53, 207-212.
42. LOVEJOY, D.B. & RICHARDSON, D.R. (2002). Novel hybrid iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective anti-proliferative activity against tumor cells. Blood, 100, 666-676.
43. MULLER, I., NIETHAMMER, D. & BRUCHELT, G. (1998). Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity. Int. J. Mol. Med., 1, 491-494.
44. MÜLLNER, E.W., NEUPERT, B. & KÜHN, L.C. (1989). A specific mRNA binding factor regulates the iron-dependent stability of the cytoplasmic transferrin receptor mRNA. Cell, 58, 373-382.
45. OLIVIERI, N.F. & BRITTENHAM, G.M. (1997). Iron chelating therapy and the treatment of thalassemia. Blood, 89, 739-761.
46. PICKART, L., GOODWIN, W.H., BURGUA, W., MURPHY, T.B. & JOHNSON, D.K. (1983). Inhibition of the growth of cultured cells and an implanted fibrosarcoma by aroylhydrazone analogs of the Gly-His-Lys-Cu(II) complex. Biochem. Pharmacol., 32, 3868-3871.
47. PONKA, P., BOROVA, J., NEUWIRT, J. & FUCHS, O. (1979a). Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett., 97, 317-321.
48. PONKA, P., BOROVA, J., NEUWIRT, J., FUCHS, O. & NECAS, E. (1979b). A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim. Biophys. Acta, 586, 278-297.
49. PORTER, J.B., GYPARAKI, M., BURKE, L.C., HUEHNS, E.R., SARPONG, P., SAEZ, V. & HIDER, R.C. (1988). Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood, 72, 1497-1503.
50. RAKBA, N., LOYER, P., GILOT, D., DELCROS, J.G., GLAISE, D., BARET, P., PIERRE, J.L., BRISSOT, P. & LESCOAT, G. (2000). Anti-proliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis, 21, 943-951.
51. RICHARDSON, D.R. & BAKER, E. (1990). The uptake of iron and transferrin by the human melanoma cell. Biochim. Biophys. Acta, 1053, 1-12.
52. RICHARDSON, D.R. & BAKER, E. (1992). Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate. J. Biol. Chem., 267, 13972-13979.
53. RICHARDSON, D.R. & BERNHARDT, P. (1999). Crystal and molecular structure of 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: An iron chelator with anti-proliferative activity. J. Biol. Inorg. Chem., 4, 266-273.
54. RICHARDSON, D.R. & MILNES, K. (1997). The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-napthylaldehyde benzoyl hydrazone. Blood, 89, 3025-3038.
55. RICHARDSON, D.R. & PONKA, P. (1994). The iron metabolism of the human neuroblastoma cell. Lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J. Lab. Clin. Med., 124, 660-671.
56. RICHARDSON, D.R., MOURALIAN, C., PONKA, P. & BECKER, E. (2001). Development of potential iron chelators for the treatment of Friedreich's ataxia: Ligands that mobilize mitochondrial iron. Biochim. Biophys. Acta, 1536, 133-140.
57. RICHARDSON, D.R., PONKA, P. & BAKER, E. (1994). The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res., 54, 685-689.
58. RICHARDSON, D.R., TRAN, E. & PONKA, P. (1995). The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents. Blood, 86, 4295-4306.
59. SAH, P. (1954). Nicotinoyl and isonicotinoyl hydrazones of pyridoxal. J. Am. Chem. Soc., 76, 300.
60. SARTORELLI, A.C., AGARAWAL, K.C., TSIFTSOGLOU, A.S. & MOORE, E.C. (1977). Characterization of the biochemical mechanism of action of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Adv. Enz. Regul., 15, 117-139.
61. SELIG, R.A., WHITE, L., GRAMACHO, C., STERLINGLEVIS, K., FRASER, I.W. & NAIDOO, D. (1998). Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res., 58, 473-478.
62. TAKEDA, E. & WEBER, G. (1981). Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci., 28, 1007-1014.
63. THELANDER, L. & GRÄSLUND, A. (1983). Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. J. Biol. Chem., 258, 4063-4066.
64. THELANDER, L. & REICHARD, P. (1979). The reduction of ribonucleotides. Annu. Rev. Biochem., 48, 133-158.
65. TORTI, S.V., TORTI, F.M., WHITMAN, S.P., BRECHBIEL, M.W., PARK, G. & PLANALP, R.P. (1998). Tumor cell cytotoxicity of a novel metal chelator. Blood, 92, 1384-1389.
66. VISWANADHAN, V.N., CHOSE, A.K., REVANKAR, G.R. & ROBINS, R.K. (1987). Atomic physiochemical parameters for 3-dimensional-structure directed quantitative structure-activity-relationships 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally-occuring nucleoside antibiotics. J. Chem. Inf. Comput. Sci., 29, 163-172.
67. ZHU, C., HUANG, Y., WEYDERT, C.J., OBERLEY, L.W. & DOMANN, F.E. (2001). Constitutive activation of transcription factor AP-2 is associated with decreased MnSOD expression in transformed human lung fibroblasts. Antioxid. Redox Signal., 3, 387-395.